BioCryst Ends Internal Programs; Biogen Cuts Apellis R&D Roles
By Dr. Zubair Khalid, DVM, MS, PhD ·
Key Takeaways
- BioCryst Pharmaceuticals is ceasing its internal research and development programs, signaling a strategic shift away from early-stage drug discovery and potentially towards prioritizing its existing approved therapies or external collaborations.
- Biogen is reducing research and development personnel within the Apellis R&D unit, a move consistent with post-acquisition portfolio rationalization and a focus on optimizing resource allocation following the 2023 acquisition.
- These workforce reductions underscore prevailing cost-containment pressures within the biotechnology sector, compelling companies to re-evaluate pipeline investments and align staffing with evolving strategic objectives.
- The cited Fierce Biotech Layoff Tracker, a crowdsourced and editorially verified resource, serves as an indicator of broader industry trends in workforce adjustments within the life sciences.
BioCryst Pharmaceuticals is ending its internal research programs, and Biogen is shedding roles in the Apellis R&D unit, according to the latest entries in the Fierce Biotech Layoff Tracker for 2026. The tracker, which monitors workforce reductions across the biotechnology industry, added these two updates without specifying the number of employees affected or the exact timeline of the cuts.
The layoff tracker is a crowdsourced and editorially verified list. Fierce Biotech encourages readers to submit tips about undisclosed reductions at biotech companies.
These workforce reductions reflect ongoing cost-containment pressures in the biotech sector. Companies are frequently reassessing pipeline priorities and trimming staff in areas that no longer align with strategic goals. For BioCryst, ending internal programs suggests a pivot away from early-stage discovery, possibly to focus on its approved products or partnerships. For Biogen, cutting R&D roles at Apellis, a company it acquired in 2023, indicates continued portfolio rationalization following the merger. Such moves are common in an industry where capital efficiency and pipeline focus are critical to survival.
Source: original report